Complications from use of sodium hyaluronate (Healonid) in anterior segment surgery

S. P. B. Percival
From Scarborough Hospital

SUMMARY Sodium hyaluronate brings an important new advance to several techniques in ophthalmic microsurgery. Its use in 226 primary lens implantations is described, and it has been found to be safe and beneficial to both surgeon and patient. Apart from a one day rise of intraocular pressure, obviated by the routine use of timolol maleate or acetazolamide, it has been found in the dosage used to be free from complication.

Sodium hyaluronate was first used in ophthalmic surgery as a vitreous substitute more than 10 years ago when its properties were shown to be elastic, highly viscous, yet nontoxic, noninflammatory, and nonantigenic. More recently Balazs, Miller, and Stegmann introduced its use into anterior segment surgery. The 1% solution (Pharmacia UK Ltd, Healonid) is at least 400,000 times more viscous than aqueous yet will pass through the fine Rycroft cannula. It is totally transparent, and because of its high molecular weight it is nonosmotic. Because of these properties and the fact that it will maintain anterior chamber depth when air may not, it has been described as the ideal medium for closed chamber surgery.

The particular assets of Healonid are that it will allow complex surgical manipulation in the anterior chamber, improving visibility while protecting the corneal endothelium and surrounding tissues from the trauma of surgical instrumentation. It may also be used to aid atraumatically the cleavage of iris synechiae or other adherent tissues. Thus Healonid has a place in the field of trauma (synechiolysis, extraction of corneal splinters penetrating the anterior chamber, anterior segment reconstruction), in keratoplasty (both for donor and recipient eye to protect endothelium), in filtration surgery (to prevent flat anterior chamber and hypotonia), in extracapsular cataract extraction (during capsulectomy and to protect endothelium from a hard lens nucleus), and in the field of lens implantation (anterior chamber manipulation, protection of endothelium, synechiolysis, iris suturing, and to maintain anterior chamber depth for secondary procedures such as keratoplasty and filtration surgery). Healonid may also be used in retinal detachment surgery (for internal tamponade).

This communication seeks to assess the possible complications that may be attributed to Healonid in the field of primary lens implantation.

Material and methods

Three hundred and thirty-four consecutive lens replacements were performed during the 29 months commencing January 1980. 244 followed planned extracapsular nucleus extraction (as described previously) with an age range 39–88, mean 73 years; 90 followed intracapsular cryoextraction after zonulysis, with an age range 56–94, mean 77 years. Healonid was used for every case when it was available. For standardisation, between 0·2 ml and 0·3 ml was used per eye whether or not the particular eye needed it. There was therefore no patient selection for the use of Healonid. No attempts were made to aspirate Healonid at the end of surgery. It was used in a total of 226 eyes to deepen the anterior chamber prior to lens implantation. Of these, 164 followed extracapsular extraction when it was also used to maintain the anterior chamber during capsulectomy and inserted to provide a cushion between lens nucleus and cornea during extraction, and 62 followed cryoextraction, 46 of which also necessitated an iris suture, placed as described by the author.

Correspondence to S. P. B. Percival, FRCS, Department of Ophthalmology, Scarborough Hospital, Scarborough, North Yorkshire.
Complications from use of sodium hyaluronate (Healonid) in anterior segment surgery

Table 1  Postoperative ocular hypertension in 334 eyes

<table>
<thead>
<tr>
<th>Eyes</th>
<th>First day</th>
<th>Mean IOP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IOP&gt;30 mmHg</td>
<td>1st day</td>
</tr>
<tr>
<td>108 Controls</td>
<td>11 (10%)</td>
<td>18-9</td>
</tr>
<tr>
<td>54 Healonid</td>
<td>17 (31%)**</td>
<td>25-6</td>
</tr>
<tr>
<td>109 Healonid+acetazolamide</td>
<td>8 (7%)**</td>
<td>19-7</td>
</tr>
<tr>
<td>63 Healonid+timolol</td>
<td>7 (11%)*</td>
<td>20-0</td>
</tr>
</tbody>
</table>

IOP=intracocular pressure.
*p<0.01; **p<0.001.

under Healonid with the chamber closed. There was only one case of aborted lens implantation during the 29 months, this being for reasons of vitreous loss.

Postoperative routine included careful slit-lamp examination by the author on the first, third, and fifteen postoperative days and more frequently when necessary. Raised intraocular pressure was treated with topical timolol maleate or systemic acetazolamide or both in combination. However, following the initial trial with 54 cases, in order to obviate further ocular hypertension, 2 subgroups of patients receiving Healonid were made: (a) during 1981 109 patients were given routine intramuscular acetazolamide 500 mg 4 hours after completion of surgery followed by tablets 250 mg q.d.s. for 2 days; (b) during 1982 63 eyes received timolol maleate 0.25% drops on completion of surgery followed by b.d. application for 2 days. Particular attention was paid to development of uveitis, wound healing, and ocular hypertension.

**POSTOPERATIVE OCULAR HYPERTENSION**

Healonid leaves the anterior chamber by way of the aqueous outflow channels, but the viscosity has to be reduced by dilution with aqueous before this hydrophilic substance may run through the trabecular meshwork. Intraocular pressure may rise therefore if excessive amounts of Healonid remain in the anterior chamber at the end of surgery.

One hundred and eight eyes did not receive Healonid or any routine ocular hypotensive. These acted as controls (Table 1). Of 54 eyes initially receiving Healonid (all were extracapsular extractions) 57% showed a rise of intraocular pressure 5 mm or more than the preoperative level. The first day applanation was over 30 mmHg in 31% and the mean intraocular pressure was 25.6 mmHg compared with 18.9 mmHg in the control group.

**Results**

In a double-blind trial on 21 normal subjects guttai timolol 0.5% has been shown to reduce the aqueous flow by 33% and tab. acetazolamide 250 mg by 27%. Of the 109 eyes in the present study receiving Healonid and routine postoperative acetazolamide the mean first-day intraocular pressure was 19.7 mmHg, and only 7% of readings were over 30 mmHg. Of the 63 eyes receiving Healonid and routine timolol the corresponding figures were 20.0 and 11% respectively.

These findings confirm the value of acetazolamide and timolol in reducing aqueous secretion, and Table 1 also shows that by the third postoperative day there was little difference in mean intraocular pressure between the different groups, the marginally higher mean pressure found in controls being explained by the fact that these eyes were less likely to have been offered treatment.

No significant difference was found between intra- and extracapsular eyes (Table 2). There were no cases of pupil block glaucoma among the groups receiving Healonid.

**Discussion**

**Uveitis**

On the first day slit-lamp examination often gives the appearance of a plastic anterior uveitis in an eye containing Healonid. However, this is due to the presence of Healonid holding cells in suspension. Flecks of blood may also be seen held in suspension due to rouleaux caused by altered electrostatic charge on red blood cells. These appearances vanish by the third day and do not require specific treatment. 7% of

Table 2  Incidence of raised intraocular pressure on first postoperative day (the initial 54 extracapsular eyes receiving Healonid are excluded)

<table>
<thead>
<tr>
<th>Eyes</th>
<th>IOP&gt;30 mmHg</th>
<th>5 mm&gt;preop.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>3 (11%)</td>
<td>5 (18%)</td>
</tr>
<tr>
<td>80 EC</td>
<td>8 (10%)</td>
<td>19 (24%)</td>
</tr>
<tr>
<td>Healonid EC</td>
<td>6 (10%)</td>
<td>26 (42%)</td>
</tr>
<tr>
<td>110 EC</td>
<td>9 (8%)</td>
<td>31 (28%)</td>
</tr>
</tbody>
</table>

IOP=intracocular pressure. IC=intracapsular. EC=extracapsular.
Healonid eyes and 8% of controls were recorded as having a more severe uveitis than is expected during the first postoperative week, but there were no cases of hypopyon or of developing keratic precipitates. There were no cases of sputtering hyphaema or of the uveitis-glaucoma-hyphaema (UGH) syndrome.

**Wound Healing**

There were no eyes in which delayed healing or improper apposition could be attributed to Healonid. A disadvantage of Healonid is that at the end of surgery it is more difficult to assess whether a wound is water-tight than when the anterior chamber is reconstituted purely with salt solution. This is of particular importance during keratoplasty, and alternative methods of reconstituting the anterior chamber should be preferred during the final phases of surgery.

**Visual Acuity**

After 17 patients had been excluded because of pre-existing visual defects unrelated to cataract all eyes were seeing 6/12 or better at the final point of follow-up except for the following: (i) macular oedema: 5 intracapsular eyes and one extracapsular eye were seeing 6/18 or less, 4 had received Healonid and two had not; (ii) retinal detachment: one intracapsular eye; (iii) corneal decompensation: one extracapsular eye that had not received Healonid.

**Conclusion**

The use of sodium hyaluronate is perhaps the single most important advance to be seen in anterior segment surgery in 10 years. It is safe and free from complications except an ocular hypertensive effect, which generally lasts for less than 3 days. This may be obviated by the routine use of postoperative timolol maleate or acetazolamide or both in combination.

**References**

Complications from use of sodium hyaluronate (Healonid) in anterior segment surgery.
S. P. Percival

doi: 10.1136/bjo.66.11.714

Updated information and services can be found at:
http://bjo.bmj.com/content/66/11/714.citation

**Email alerting service**
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/